These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33837670)

  • 1. Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications.
    Syed T; Siddiqui MS
    Liver Transpl; 2021 Sep; 27(9):1326-1333. PubMed ID: 33837670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients.
    Idowu MO; Chhatrala R; Siddiqui MB; Driscoll C; Stravitz RT; Sanyal AJ; Bhati C; Sargeant C; Luketic VA; Sterling RK; Contos M; Matherly S; Puri P; Siddiqui MS
    Liver Transpl; 2015 Nov; 21(11):1395-402. PubMed ID: 26228654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease.
    Patel S; Siddiqui MB; Roman JH; Zhang E; Lee E; Shen S; Faridnia M; Mintini RJ; Boyett S; Idowu MO; Sanyal AJ; Luketic VA; Siddiqui MS
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2202-2204. PubMed ID: 33007508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of serum atherogenic risk in liver transplant recipients: Role of lipoproteins and metabolic and inflammatory markers.
    Chhatrala R; Siddiqui MB; Stravitz RT; Driscoll C; Sanyal A; Sargeant C; Luketic V; Sharma A; Sterling R; Matherly S; Puri P; Siddiqui MS
    Liver Transpl; 2015 May; 21(5):623-30. PubMed ID: 25762084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: A focus on atherogenic dyslipidemia.
    Amor AJ; Pinyol M; Solà E; Catalan M; Cofán M; Herreras Z; Amigó N; Gilabert R; Sala-Vila A; Ros E; Ortega E
    J Clin Lipidol; 2017; 11(2):551-561.e7. PubMed ID: 28502513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyslipidemia in nonalcoholic fatty liver disease.
    Amor AJ; Perea V
    Curr Opin Endocrinol Diabetes Obes; 2019 Apr; 26(2):103-108. PubMed ID: 30694825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
    Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M
    Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small Dense Low-Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients.
    Siddiqui MB; Arshad T; Patel S; Lee E; Albhaisi S; Sanyal AJ; Stravitz RT; Driscoll C; Sterling RK; Reichman T; Bhati C; Siddiqui MS
    Hepatology; 2019 Jul; 70(1):98-107. PubMed ID: 30672598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases.
    Dabravolski SA; Bezsonov EE; Baig MS; Popkova TV; Orekhov AN
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
    Simon TG; Corey KE; Chung RT; Giugliano R
    Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation.
    Kim H; Lee K; Lee KW; Yi NJ; Lee HW; Hong G; Choi Y; You T; Suh SW; Jang JJ; Suh KS
    Clin Transplant; 2014 May; 28(5):521-9. PubMed ID: 24579874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interpreting lipoproteins in nonalcoholic fatty liver disease.
    Nemes K; Åberg F
    Curr Opin Lipidol; 2017 Aug; 28(4):355-360. PubMed ID: 28441156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.
    Santos RD; Valenti L; Romeo S
    Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD.
    Mavromati M; Jornayvaz FR
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk, atherosclerosis and metabolic syndrome after liver transplantation: a mini review.
    Oliveira CP; Stefano JT; Alvares-da-Silva MR
    Expert Rev Gastroenterol Hepatol; 2013 May; 7(4):361-4. PubMed ID: 23639094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression to Cirrhosis Leads to Improvement in Atherogenic Milieu.
    Patel S; Siddiqui MB; Chandrakumaran A; Rodriguez VA; Faridnia M; Hernandez Roman J; Zhang E; Patrone MV; Kakiyama G; Walker C; Sima A; Minniti RJ; Boyett S; Bajaj JS; Sanyal A; Pandak WM; Bhati C; Siddiqui MS
    Dig Dis Sci; 2021 Jan; 66(1):263-272. PubMed ID: 32189102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders.
    Lim S; Oh TJ; Koh KK
    Int J Cardiol; 2015 Dec; 201():408-14. PubMed ID: 26310987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.